Drug Trial Radar · NCT06957418
Alzheimer's Tau Platform: Master Protocol
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Paul S. AisenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA); University of California, San Francisco; Massachusetts General Hospital; Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium
- First posted
- May 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This platform trial allows for the simultaneous testing of multiple tau therapies under a shared master protocol. This means that multiple investigational products will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. The main questions the platform trial aims to answer are: * Does a tau-directed therapy, alone or in combination with donanemab, reduce tau buildup in the brain compared to donanemab alone? * Does a tau-directed therapy, alone or in combination with donanemab, slow disease progression based on brain imaging, fluid biomarkers, and measures of memory and thinking? Participants will: * Be randomized to a treatment regimens, each containing different tau therapies. The exact number of treatment regimens that will active at the time of screening will change over time. * Receive donanemab or placebo for 6 months, followed by 24 months of tau therapy alone or in combination with donanemab. * Undergo regular cognitive testing, brain scans (MRI/PET), and biomarker assessments over 30 months Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to one of three arms: (1) tau therapy alone, (2) a combination of donanemab and tau therapy, or (3) donanemab alone. New regimens will be continuously added as new investigational products become available. The Alzheimer's Tau Platform Trial will enroll additional participants as each new regimen becomes available. ATP will launch with one regimen: Regimen A: AADvac1. In the future, Regimen B ("Tau2") will launch with a second tau directed therapy.
Conditions
- Preclinical Alzheimer's Disease
- Alzheimer Disease
- Prodromal Alzheimer's Disease
Interventions
AADvac1Drug
AADvac1 tau directed therapy
Tau2Drug
Tau2 directed therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of brain tau deposition as measured by tau positron emission tomography (PET)Time frame: 0, 6, 18 and 30 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Banner Alzheimer's Institute
Phoenix, Arizona · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
University of Kentucky Sanders Brown Center on Aging
Lexington, Kentucky · Recruiting
Brigham and Women's Hospital Center for Alzheimer Research and Treatment
Boston, Massachusetts · Recruiting
Butler Hospital Memory and Aging Program
Providence, Rhode Island · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Harborview Medical Center, University of Washington
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.